Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s traded shares stood at 1.38 million during the last session, with the company’s beta value hitting 1.50. At the close of trading, the stock’s price was $6.24, to imply an increase of 12.23% or $0.68 in intraday trading. The GLUE share’s 52-week high remains $12.40, putting it -98.72% down since that peak but still an impressive 48.56% since price per share fell to its 52-week low of $3.21. The company has a valuation of $383.37M, with an average of 1.09 million shares in intraday trading volume over the past 10 days and average of 2.81 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Monte Rosa Therapeutics Inc (GLUE), translating to a mean rating of 1.29. Of 5 analyst(s) looking at the stock, 0 analyst(s) give GLUE a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.11.
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) trade information
After registering a 12.23% upside in the last session, Monte Rosa Therapeutics Inc (GLUE) has traded red over the past five days. The 5-day price performance for the stock is -4.37%, and -19.90% over 30 days. With these gigs, the year-to-date price performance is -10.09%. Short interest in Monte Rosa Therapeutics Inc (NASDAQ:GLUE) saw shorts transact 9.14 million shares and set a 5.1 days time to cover.
Monte Rosa Therapeutics Inc (GLUE) estimates and forecasts
Looking at statistics comparing Monte Rosa Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Monte Rosa Therapeutics Inc (GLUE) shares are 28.13% up over the last 6 months, with its year-to-date growth rate higher than industry average at 43.35% against 16.70%.
Revenue forecast for the current quarter as set by 7 analysts is 51.19M. Meanwhile, for the current quarter, a total of 5 analyst(s) estimate revenue growth to 4.88M.
GLUE Dividends
Monte Rosa Therapeutics Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s Major holders
Monte Rosa Therapeutics Inc insiders hold 0.70% of total outstanding shares, with institutional holders owning 90.67% of the shares at 91.32% float percentage. In total, 90.67% institutions holds shares in the company, led by NEA MANAGEMENT COMPANY, LLC. As of 2024-06-30, the company held over 7.69 million shares (or 12.7872% of shares), all amounting to roughly $28.77 million.
The next major institution holding the largest number of shares is PRICE T ROWE ASSOCIATES INC /MD/ with 5.98 million shares, or about 9.9368% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $22.36 million.
We also have Price (T.Rowe) New Horizons Fund and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Monte Rosa Therapeutics Inc (GLUE) shares. Going by data provided on Sep 30, 2024 , Price (T.Rowe) New Horizons Fund holds roughly 3.41 shares. This is just over 5.54% of the total shares, with a market valuation of $21.25 million. Data from the same date shows that the other fund manager holds a little less at 1.35, or 2.20% of the shares, all valued at about 8.42 million.
